Androgen deficiency in the aging male

Size: px
Start display at page:

Download "Androgen deficiency in the aging male"

Transcription

1 Androgen deficiency in the aging male Practice Committee of the American Society for Reproductive Medicine in collaboration with the Society for Male Reproduction and Urology The American Society for Reproductive Medicine, Birmingham, Alabama The purpose of this Educational Bulletin is to review current methods of evaluation, the indications for treatment, and to provide recommendations for treatment of androgen deficiency in the aging male (ADAM). (Fertil Steril Ò 2008;90:S83 7. Ó2008 by American Society for Reproductive Medicine.) Serum testosterone levels decline as men age (1, 2). In a portion of older men (over 50 years), this decline may result in clinical symptoms and signs of androgen deficiency, or andropause. Although guidelines for androgen replacement therapy for older men have been developed by several groups (3 5), the data to support treatment are based on the results of only a small number of clinical trials (6). It has not been established definitively that the decline in testosterone observed in most aging men results in an androgendeficient state having health implications that can be avoided or ameliorated by androgen therapy (7 10). The purpose of this document is to review current methods of evaluation, the indications for treatment, and to provide recommendations for treatment of androgen deficiency in the aging male (ADAM). INDICATIONS FOR TREATMENT Symptoms and Signs Symptoms associated with low testosterone levels in the aging male include low libido (with or without erectile dysfunction) (11); decreased strength, energy, or stamina (12); increased irritability or decreased enjoyment of life (13); and alterations in certain components of cognitive function (14). Physical findings that may be due to androgen deficiency include osteopenia/osteoporosis (15), loss of muscle mass (16), increased visceral adipose (17), testicular atrophy, and gynecomastia. Age-related androgen deficiency may be worsened by significant abdominal obesity leading to elevated levels of estrogens and sex hormone binding globulin (SHBG) (18), by liver disease, or by certain medications. Several published validated questionnaires provide the means for assessing the clinical manifestations of testosterone deficiency in older men (19 21). However, scores derived from such questionnaires do not predict or correlate well with measured free and total testosterone levels (22) and thus lack specificity for the clinical diagnosis of ADAM (23 25). Educational Bulletin Revised August No reprints will be available. Laboratory Evaluations Serum testosterone should be evaluated only in men with signs or symptoms of androgen deficiency. Serum total testosterone is composed of free, albumin-bound, and SHBGbound components. The combination of free testosterone and albumin-bound testosterone is denoted as bioavailable testosterone which, in epidemiologic studies, is the component that best correlates with parameters such as bone mineral density (12), sexual function (26), and cognition (27). However, it is by no means established that bioavailable testosterone represents the effective and clinically relevant fraction of total testosterone for every androgen target organ. Some effects of testosterone may reflect the actions of its metabolites, such as estradiol in bone and dihydrotestosterone in the prostate. Because SHBG levels increase with age, the agerelated decline in serum bioavailable testosterone is much greater than for total testosterone (28). The laboratory assay for serum total testosterone is widely available, but it may lead to misclassification of some men who would be considered androgen deficient on the basis of bioavailable or free testosterone levels. However, the accuracy of some methods for the measurement of free testosterone levels has been challenged (29), and bioavailable testosterone assays are not widely available. A recent trend toward measurement of total testosterone and SHBG has emerged, allowing calculation of a free testosterone index (FTI: total testosterone/shbg) as an indication of the amount of bioavailable testosterone. Regardless of which component of serum testosterone is measured, blood samples should be obtained in the morning because of the circadian variation and pulsatile nature of testosterone secretion. Currently there is no established consensus on the hormonal and clinical criteria for identifying older men who are candidates for androgen therapy. Therefore, current recommendations are based on expert opinion, and there is an urgent need for additional studies to better define which patients are likely to benefit from androgen therapy. Consensus recommendations issued by the Endocrine Society have proposed that total testosterone levels below 200 ng/dl (<6.9 nmol/l) identify hypogonadism that warrants treatment, unless contraindicated (as discussed later). The recommendations further suggest that men with levels between 200 and 400 ng/dl ( nmol/l) may benefit from therapy, and that androgen deficiency is unlikely in men with total testosterone concentrations above 400 ng/dl (3). Measuring free or bioavailable testosterone or calculating the FTI may be useful in the evaluation of men who might benefit from /08/$34.00 Fertility and Sterility â Vol. 90, Suppl 3, November 2008 S83 doi: /j.fertnstert Copyright ª2008 American Society for Reproductive Medicine, Published by Elsevier Inc.

2 androgen treatment. Values for bioavailable testosterone that are below the normal range for normal young adult men, or a FTI less than nmol/nmol (1), support the diagnosis of androgen deficiency. The serum luteinizing hormone (LH) should be measured as part of the evaluation of an older man with androgen deficiency to detect secondary hypogonadism (of hypothalamicpituitary origin.) Serum gonadotropin levels rise modestly with age, but few older men have values outside the normal range for young adult men. Further evaluation with serum prolactin and pituitary magnetic resonance imaging (MRI) is warranted when the total testosterone level is very low (<150 ng/ dl, <5.2 nmol/l) and the serum LH is normal or low. DECISION TO TREAT Men aged over 50 years should be considered candidates for androgen therapy if they have [1] clinical manifestations indicative of ADAM (osteopenia, decreased muscle mass and strength, decline in stamina and energy, low libido, loss of erectile quality, irritability, impaired cognition, or other mood changes); [2] a low serum testosterone, bioavailable testosterone, or FTI; and [3] no contraindications to treatment. Because the long-term health risks and benefits of androgen therapy for androgen deficiency in the older man have not been defined, it is important to monitor treated patients for both efficacy and safety. At a minimum, the physical examination before therapy begins should include the breasts, heart, lungs, and prostate to exclude preexisting gynecomastia, cardiovascular abnormalities, or prostatic conditions that may be exacerbated by treatment. A pretreatment serum prostate specific antigen (PSA) test and complete blood count also should be obtained. Prostate biopsy is recommended when the digital rectal examination or PSA result is abnormal. It is premature to recommend preventive androgen therapy in older men with androgen deficiency. Most older men are relatively hypogonadal and should be considered as candidates for androgen therapy only when they have symptoms or physiologic findings that reasonably can be attributed to androgen deficiency. Such physiologic findings and symptoms have a complicated pathogenesis and could be affected by a variety of factors. THERAPEUTIC AGENTS AND MONITORING DURING TREATMENT Therapeutic Agents All commercial androgen formulations currently available in the United States are preparations of testosterone, an androgen that can be converted to estradiol. Estradiol may be the major sex steroid affecting male bone density (30). The efficacy of testosterone therapy should be determined on an individual basis. There is no evidence that clinical response differs with the testosterone formulation employed; the benefits of treatment depend on the serum testosterone level that is achieved. The goal of androgen therapy is to raise testosterone levels over pretreatment values without exceeding the normal range for young adult males. No dose-effect of androgen therapy has been demonstrated. However, dose escalation to increase efficacy may lead to an increase in side effects (31). The major forms of testosterone delivery available in the United States and considered safe for use in older men are listed in Table 1. The oral methylated testosterones are not listed and should not be used because of their potential for liver toxicity. Selection is based on patient preference, the serum testosterone levels that can be obtained, and the potential side effects unique to the mode of testosterone delivery (see Table 1). Dehydroepiandrosterone (DHEA), a progenitor of testosterone and other sex steroids, is commercially available in oral form as an unregulated health supplement. When used in standard replacement doses ( mg/day) in older men, DHEA does not significantly increase serum testosterone levels (32), although higher doses may. No data relating to the efficacy of DHEA for the treatment of androgen deficiency in older men are available. Monitoring During Treatment Within the first 2 to 3 months after treatment begins, older men receiving testosterone therapy should be seen to evaluate the clinical response and to identify possible adverse effects of treatment, including weight gain, peripheral edema, gynecomastia, breast tenderness, symptoms of benign prostatic hyperplasia, or problems with sleep; a digital rectal examination of the prostate also should be performed. The testosterone level should be measured to determine whether the treatment regimen is achieving its intended goals. The optimal time to measure the testosterone level varies with the mode of treatment (see Table 1). Because therapy is empiric, the clinical response may help to guide therapy more than the testosterone level. The questionnaires used for the initial evaluation of ADAM also can be used to monitor the efficacy of treatment (15). Safety monitoring parameters should include measurements of hemoglobin or hematocrit and serum PSA. The PSA level is especially important because PSA production is androgen dependent and a rapid rise (>1.0 ng/ml) within the first 3 to 6 months of therapy may reflect the presence of a preexisting unrecognized cancer (33). In men who exhibit a significant increase in serum PSA, androgen therapy should be discontinued until a thorough prostate evaluation can be accomplished. There is no evidence that androgen therapy has adverse effects on liver function or lipoprotein levels in older men; consequently, such monitoring during treatment is unnecessary for most men. When there is no evidence of adverse effects, the serum testosterone level is within the therapeutic range, and therapy is judged efficacious, evaluation should be repeated within 3 months, again 6 months later, and then at least annually S84 ASRM Practice Committee Androgen Deficiency in the Aging Male Vol. 90, Suppl 3, November 2008

3 TABLE 1 Testosterone delivery systems available in the United States. Preparation Initial treatment dose for older men Time to peak testosterone Timing of testosterone testing during treatment Possible specific side effects Injectable esters Pain at injection Testosterone mg 2 3 days 1 week site, mood swings, enanthate ( mg/ml; 10 ml) every 2 weeks or mg/week elevated hematocrit Testosterone mg every 2 3 days 1 week cypionate ( mg/ml; 10 ml) 2 weeks or mg/week Testosterone pellets 225 mg/4 6 months 1 month 3 4 months Local site infection, extravasation of pellet, mood swings, elevated hematocrit Patches Scrotal (Testoderm: 40 cm 2 ; 1 patch/day 3 5 hour 12 hours Local site irritation 40 cm 2 or 60 cm 2 ) Nonscrotal (Androderm: 2.5 mg or 5.0 mg) 5 mg/day 6 10 hours 12 hours Skin irritation, urticaria Gel (Testim, Androgel: 2.5-g, 5.0-g packet) 5 g/day Constant 2 4 week Occasional mild skin irritation Notes: Androderm, Watson Pharma, Morristown, NJ. Androgel, Solvay, Marietta, GA. Testim, Auxilium, East Norriton, PA. ASRM Practice Committee. Androgen Deficiency in the Aging Male. Fertil Steril thereafter. A complete blood count, serum PSA, and testosterone level should be obtained 3 and 6 months after treatment begins and at least annually afterward. If osteoporosis was an indication for androgen therapy, bone mineral density should be reevaluated after approximately 2 years of treatment. Risks of Treatment The potential risks of androgen therapy in older men include fluid retention, gynecomastia, excessively elevated red blood cell mass, exacerbation of sleep apnea or benign or malignant prostate disease, and an increase in risk for cardiovascular disease (CVD). The fluid retention and gynecomastia are usually mild and occur infrequently in men with testosterone levels in the normal range. Although new or worsening sleep apnea during testosterone treatment has been observed (34), it appears to be infrequent. An increase in red blood cell mass leading to polycythemia also may occur during testosterone therapy in older men. Fertility and Sterility â Concerns that treatment may aggravate CVD are theoretical and based largely on observations that CVD is more common in men than in age-matched women. However, in epidemiologic studies, low testosterone levels are more predictive of CVD than high levels in men; low testosterone levels have been associated with an increased risk for development of atherosclerosis (35) and the metabolic syndrome, which is a precursor of CVD (36). Other studies have demonstrated that testosterone has arterial vasodilatory (37) and anti-ischemic effects (38). Androgen therapy in older men generally has been observed to improve, rather than worsen, atherosclerotic lipid profiles (3). The inverse relationship between testosterone levels and the risk for CVD has been well documented (39, 40) and suggests that testosterone therapy may be offered without serious concerns about potential adverse cardiovascular effects (40). Large randomized clinical trials are required to better define the effects of testosterone treatment on CVD risk. Another theoretical concern is that testosterone treatment may exacerbate benign prostatic hyperplasia or incident prostate cancer, although studies of the effects of testosterone therapy undertaken thus far have observed little or no change in PSA (41), no increase in symptoms of benign prostatic hyperplasia, and no increased propensity for development of prostate cancer. Nevertheless, experience with androgen therapy in older men still is too limited to allow confident conclusions regarding any associated long-term risks of prostatic disease (7). Although rarely of clinical importance in S85

4 older men, exogenous androgen supplementation may decrease sperm production significantly. The absolute contraindications to androgen therapy in older men are [1] clinical prostate cancer, [2] a previous history or current evidence of breast cancer, [3] an elevated hematocrit (>55%), and [4] sensitivity to any of the ingredients in androgen formulations. Relative contraindications to androgen therapy include [1] severe obstructive sleep apnea, [2] a hematocrit between 52% and 55%, [3] severe symptoms in the lower urinary tract related to benign prostatic hyperplasia, and [4] medical conditions wherein modest fluid retention may be harmful (e.g., congestive heart failure). There is some evidence to suggest that hypogonadal men may be at increased risk for unsuspected prostate cancer because PSA production is falsely low due to low circulating androgen levels (33, 42). However, because PSA levels in hypogonadal men with prostate cancer are likely to increase rapidly during androgen treatment, therapy actually may facilitate detection of prostate cancer when monitored appropriately. SUMMARY AND RECOMMENDATIONS Androgen deficiency in the aging male may be associated with changes in mood, body composition, stamina, energy, and decreased sexual and cognitive function as well as loss of bone mineral density. Such signs and symptoms may be relieved or eliminated with testosterone replacement therapy. Serum testosterone should be evaluated only in men with signs or symptoms of androgen deficiency. Androgen therapy should be considered for men who have symptoms of androgen deficiency and a low serum total testosterone concentration (<200 ng/dl). Free or bioavailable testosterone levels or the free testosterone index should be evaluated in men who have symptoms of androgen deficiency and a borderline total serum testosterone concentration between 200 ng/dl and 400 ng/dl. During androgen therapy, serum testosterone, PSA, and hematocrit should be monitored, and periodic digital rectal examination is recommended. Limited data regarding the benefits and risks of testosterone replacement therapy do not permit specific treatment recommendations at this time. Further randomized clinical trials are required to better define the effects of androgen replacement therapy in aging men. Acknowledgments: This report was developed under the direction of the Practice Committee of the American Society for Reproductive Medicine as a service to their members and other practicing clinicians. Although this document reflects appropriate management of a problem encountered in the practice of reproductive medicine, it is not intended to be the only approved standard of practice or to dictate an exclusive course of treatment. Other plans of management may be appropriate, taking into account the needs of the individual patient, available resources, and institutional or clinical practice limitations. This report was approved by the Board of Directors of the American Society for Reproductive Medicine. REFERENCES 1. Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR. Longitudinal effects of aging on serum total and free testosterone in healthy men. J Clin Endocrinol Metab 2001;86: Arujo AB, O Donnell AB, Brambilla DJ, Simpson WB, Longcope C, Matsumoto AM, McKinlay JB. Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts Male Aging Study. J Clin Endocrinol Metab 2004;89: Swerdloff RS, Chair. Proceedings of the Endocrine Society Andropause Consensus Conferences Continuing Medical Education Series. Chevy Chase, MD: The Endocrine Society, Morales A, Lunenfeld B. Standards, guidelines, and recommendations of the International Society for the Study of the Aging Male (ISSAM): androgen replacement therapy in aging men with secondary hypogonadism. Aging Male 2001;4: Liu PY, Swerdloff RS, Veldhuis JD. Clinical review 171. The rationale, efficacy and safety of androgen therapy in older men: future research and current practice recommendations. J Clin Endocrinol Metab 2004;89: Lunenfeld B, Saad F, Hoesl CE. ISA, ISSAM and EAU recommendations for the investigation, treatment and monitoring of late-onset hypogonadism in males: scientific background and rationale. Aging Male 2005;8: Report of National Institute on Aging advisory panel on testosterone replacement in men. J Clin Endocrinol Metab 2001;86: Tan RS, Culberson JW. An integrative review on current evidence of testosterone replacement therapy for the treatment of andropause. Maturitas 2003;45: Hijazi RA, Cunningham GR. Andropause: Is androgen replacement therapy indicated for the aging male? Annu Rev Med 2005;56: T Sjoen G, Kaufman JM. Androgen deficiency in aging men. Curr Opin Endocrinol Diabetes Obes 2006;13: Korenman SG, Morley JE, Mooradian AD, Davis SS, Kaiser FE, Silver AJ, et al. Secondary hypogonadism in older men: its relation to impotence. J Clin Endocrinol Metab 1990;71: van den Beld AW, de Jong FH, Grobbee DE, Pols HA, Lamberts SW. Measures of bioavailable serum testosterone and estradiol and their relationship with muscle strength, bone density, and body composition in elderly men. J Clin Endocrinol Metab 2000;85: Sternbach H. Age-associated testosterone decline in men: clinical issues for psychiatry. Am J Psychiatry 1998;155: Janowsky JS, Oviatt SK, Orwoll ES. Testosterone influences spatial cognition in older men. Behav Neurosci 1994;108: Greendale G, Edelstein S, Barrett-Connor E. Endogenous sex steroid and bone mineral density in older women and men (the Rancho Bernardo Study). J Bone Miner Res 1997;12: Vermeulen A, Goemaere S, Kaufman JM. Sex hormones, body composition, and aging. Aging Male 1999;2: Turner HE, Wass JA. Gonadal function in men with chronic illness. Clin Endocrinol 1997;47: Couillard C, Gagnon J, Bergeron J, Leon AS, Rao DC, Skinner JS, et al. Contribution of body fatness and adipose tissue distribution to the age variation in plasma steroid hormone concentrations in men: the HERITAGE Family Study. J Clin Endocrinol Metab 2000;85: Morley JE, Charlton E, Patrick P, Kaiser FE, Cadeau P, McCready D, et al. Validation of a screening questionnaire for androgen deficiency in aging males. Metabolism 2000;49: Smith KW, Feldman HA, McKinlay JB. Construction and field validation of a self-administered screener for testosterone deficiency (hypogonadism) in ageing men. Clin Endocriol 2000;53: Heinemann LAJ, Saad F, Thiele K, Wood-Dauphinee S. The aging males symptoms rating scale: cultural and linguistic validation into English. Aging Male 2001;4: T Sjoen G, Goemaere S, De Meyere M, Kaufman J-M. Perception of males aging symptoms, health and well-being in elderly communitydwelling men is not related to circulating androgen levels. Psychoneuroendocrinology 2004;29: S86 ASRM Practice Committee Androgen Deficiency in the Aging Male Vol. 90, Suppl 3, November 2008

5 23. Tancredi A, Reginster J-Y, Schleich F, Pire G, Maassen P, Luyckx F, Legros J-J. Interest of the Androgen Deficiency in Aging Males (ADAM) questionnaire for the identification of hypogonadism in elderly community-dwelling male volunteers. Eur J Endocrinol 2004;151: Mosely JE, Perry HM III, Kevorkian RT, Patrick P. Comparison of screening questionnaires for the diagnosis of hypogonadism. Maturitas 2006;53: Lin YC, Hwang TIS, Chiang HS, Yang CR, WU HC, Wu TL, Huang SP. Correlations of androgen deficiency with clinical symptoms in Taiwanese males. Int J Impot.Res 2006;18: Nilsson P, Moller L, Solstad K. Adverse effects of psychosocial stress on gonadal function and insulin levels in middle aged males. J Intern Med 1995;237: Moffat SD, Zonderman AB, Metter EJ, Blackman MR, Harman SM, Resnick SM. Longitudinal assessment of serum free testosterone concentration predicts memory performance and cognitive status in elderly men. J Clin Endocrinol Metab 2002;87: Mohr BA, Bhasin S, Link CL, O Donnell AB, McKinlay JB. The effect of changes in adiposity on testosterone levels in older men: longitudinal results from the Massachusetts Male Aging Study. Eur J Endocrinol 2006;155: Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 1999;84: Khosla S, Melton LJ 3rd, Atkinson EJ, O Fallon WM, Klee GG, Riggs BL. Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men: a key role for bio-available estrogen. J Clin Endocrinol Metab 1998;83: Liu PY, Swerdloff RS, Veldhuis JD. The rationale, efficacy and safety of androgen therapy in older men: future research and current practice recommendations. J Clin Endocrinol Metab 2004;89: Morales AJ, Nolan JJ, Nelson JC, Yen SS. Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age. J Clin Endocrinol Metab 1994;78: Bhasin S, Singh AB, Mac RP, Carter B, Lee MI, Cunningham GR. Managing the risks of prostate disease during testosterone replacement therapy in older men: recommendations for a standardized monitoring plan. J Androl 2003;24: Matsumoto AM, Sandblom RE, Schoene RB, Lee KA, Giblin EC, Pierson DJ, et al. Testosterone replacement in hypogonadal men: effects on obstructive sleep apnoea, respiratory drives, and sleep. Clin Endocrinol 1985;22: HakAE, WittemanJC, de Jong FH, Geerlings MI,Hofman A, Pols HA. Low levels of endogenous androgens increase the risk of atherosclerosis in elderly men; the Rotterdam Study. J Clin Endocrinol Metab 2002;87: Kupelian V, Page ST, Araujo AB, Travison TG, Bremner WJ, McKinlay JB. Low sex hormone-binding globulin, total testosterone, and symptomatic androgen deficiency are associated with development of the metabolic syndrome in nonobese men. J Clin Endocrinol Metab 2006;91: Webb CM, McNeill JG, Hayward CS, de Zeigler D, Collins P. Effects of testosterone on coronary vasomotor regulation in men with coronary heart disease. Circulation 1999;100: Webb CM, Adamson DL, de Zeigler D, Collins P. Effect of acute testosterone on myocardial ischemia in men with coronary artery disease. Am J Cardiol 1999;83: Liu PY, Death DK, Handelsman DJ. Androgens and cardiovascular disease. Endocrinol Rev 2003;24: Wu FCW, von Eckardstein A. Androgens and coronary artery disease. Endocrinol Rev 2003;24: Tenover JS. Experience with testosterone replacement in the elderly. Mayo Clin Proc 2000;75(Suppl):S Morgentaler A, Bruning CO 3rd, DeWolf WC. Occult prostate cancer in men with low serum testosterone levels. JAMA 1996;276: Fertility and Sterility â S87

Treatment of androgen deficiency in the aging male

Treatment of androgen deficiency in the aging male Treatment of androgen deficiency in the aging male The Practice Committee of the American Society for Reproductive Medicine Birmingham, Alabama Although guidelines for androgen replacement therapy for

More information

Original Research Declining testicular function in aging men

Original Research Declining testicular function in aging men (2003) 15, Suppl 4, S3 S8 & 2003 Nature Publishing Group All rights reserved 0955-9930/03 $25.00 www.nature.com/ijir Original Research 1 * 1 Wesley Woods Health Center, Atlanta, Georgia, USA Age-related

More information

Issues. What is a low testosterone? Who needs testosterone therapy? Benefits/adverse effects of testosterone replacement Treatment options

Issues. What is a low testosterone? Who needs testosterone therapy? Benefits/adverse effects of testosterone replacement Treatment options Male Hypogonadism Jauch Symposium Waterloo, IA May 17, 2013 Janet A. Schlechte, M.D. Disclosure of Financial Relationships Janet A. Schlechte, M.D. has no relationships with any proprietary entity producing

More information

Donald W. Morrish, MD, PhD, FRCPC Presented at Mountain Man: Men's Health Conference, May Terry s Testosterone

Donald W. Morrish, MD, PhD, FRCPC Presented at Mountain Man: Men's Health Conference, May Terry s Testosterone Focus on CME at University of Alberta ADAM: Dealing with the Decline Donald W. Morrish, MD, PhD, FRCPC Presented at Mountain Man: Men's Health Conference, May 2005 We now know there is a decline in total

More information

Testosterone Hormone Replacement Drug Class Prior Authorization Protocol

Testosterone Hormone Replacement Drug Class Prior Authorization Protocol Testosterone Hormone Replacement Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective date: April 1, 2018 This policy has been developed through

More information

Testosterone Hormone Replacement Drug Class Prior Authorization Protocol

Testosterone Hormone Replacement Drug Class Prior Authorization Protocol Line of business: Medi-Cal Effective Date: August 16, 2017 Revision Date: August 16, 2017 Testosterone Hormone Replacement Drug Class Prior Authorization Protocol This policy has been developed through

More information

Drug Class Monograph

Drug Class Monograph Drug Class Monograph Class: Testosterone Hormone Replacement Drug: Androderm (testosterone transdermal system), Androgel (testosterone topical gel), Axiron (testosterone topical solution), Aveed (testosterone

More information

HARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES

HARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES Generic Brand HICL GCN Exception/Other METHYL ANDROID METHITEST METHYL TESTRED 01404 ROUTE MISCELL. CYPIONATE ENANTHATE GUIDELINES FOR USE ANDRODERM ANDROGEL AXIRON FORTESTA NATESTO STRIANT TESTIM VOGELXO

More information

Insight into male menopause'

Insight into male menopause' Insight into male menopause' Dr Mark Vanderpump MD FRCP Consultant Endocrinologist Clinics: Tuesday PM Mark Vanderpump Consultant Physician and Endocrinologist Introduction Serum total and free testosterone

More information

Androgens and Anabolic Steroids Prior Authorization with Quantity Limit - Through Preferred Topical Androgen Agent

Androgens and Anabolic Steroids Prior Authorization with Quantity Limit - Through Preferred Topical Androgen Agent Androgens and Anabolic Steroids Prior Authorization with Quantity Limit - Through Preferred Topical Androgen Agent Androgens/Anabolic Steroids Prior Authorization with Quantity Limit Through Preferred

More information

Chapter 5. General discussion

Chapter 5. General discussion Chapter 5. General discussion 127 Chapter 5 In 2003, two review papers concluded that endogenous androgens do not show any consistent association with cardiovascular disease (CVD) risk 1,2. Apparently,

More information

UnitedHealthcare Pharmacy Clinical Pharmacy Programs

UnitedHealthcare Pharmacy Clinical Pharmacy Programs UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 2018-9 Program Prior Authorization/Medical Necessity Topical Androgens Medication Axiron*, Androderm, Androgel*, Fortesta*, Natesto*,

More information

Natural Hair Transplant Medical Center, Inc Dove Street, Suite #250, Newport Beach, CA Phone

Natural Hair Transplant Medical Center, Inc Dove Street, Suite #250, Newport Beach, CA Phone Natural Hair Transplant Medical Center, Inc. 1000 Dove Street, Suite #250, Newport Beach, CA 92660 Phone-949-622-6969 Finasteride (PROPECIA ) Acknowledgement Finasteride is an oral medication, manufactured

More information

Secrets of Abang Sado : Effects of testosterone therapy. Azraai Nasruddin

Secrets of Abang Sado : Effects of testosterone therapy. Azraai Nasruddin + Secrets of Abang Sado : Effects of testosterone therapy Azraai Nasruddin + Testosterone Testosterone : Steroid hormone - Made primarily by the testicles in males - Small amounts produced by the adrenal

More information

M0BCore Safety Profile. Pharmaceutical form(s)/strength: 5 mg SE/H/PSUR/0002/006 Date of FAR:

M0BCore Safety Profile. Pharmaceutical form(s)/strength: 5 mg SE/H/PSUR/0002/006 Date of FAR: M0BCore Safety Profile Active substance: Finasteride Pharmaceutical form(s)/strength: 5 mg P-RMS: SE/H/PSUR/0002/006 Date of FAR: 16.05.2014 4.3 Contraindications Finasteride is not indicated for use in

More information

The ICL Insider. Lab Testing: Testosterone. In This Issue. The Debate

The ICL Insider. Lab Testing: Testosterone. In This Issue. The Debate The ICL Insider February 2017 Volume 2, Issue 2 Lab Testing: Testosterone In This Issue Testosterone shashtilak@iclabs.ca Next Issue: Expected Release April 2017 The Debate Aging is accompanied by various

More information

Affirming Care of the Transgender Patient

Affirming Care of the Transgender Patient Mountain West AIDS Education and Training Center Affirming Care of the Transgender Patient Jessica Rongitsch, MD, FACP This presentation is intended for educational use only, and does not in any way constitute

More information

Jeremiah Murphy, MD Mercy Urology Clinic. October 21, 2017

Jeremiah Murphy, MD Mercy Urology Clinic. October 21, 2017 Jeremiah Murphy, MD Mercy Urology Clinic October 21, 2017 Describe an appropriate strategy for the evaluation and diagnosis of male hypogonadism Endocrine Society Clinical Practice Guideline-2010 Review

More information

Testosterone Topical/Buccal/Nasal

Testosterone Topical/Buccal/Nasal BENEFIT APPLICATION Testosterone Topical/Buccal/Nasal DRUG POLICY Benefit determinations are based on the applicable contract language in effect at the time the services were rendered. Exclusions, limitations

More information

MI Androgen Deficiency Hypogonadism

MI Androgen Deficiency Hypogonadism MI Androgen Deficiency Hypogonadism WADA TUE Expert Group John A Lombardo, MD October 2014, Columbus, Ohio USA Hypothalamic-Pituitary-Gonadal Axis / 2 Hypogonadism/Androgen Deficiency Clinical syndrome:

More information

Current Data and Considerations Novel Testosterone Formulations

Current Data and Considerations Novel Testosterone Formulations Current Data and Considerations Novel Testosterone Formulations 1 Current and Novel Therapeutic Options Module 4 2 Objectives Identify desirable characteristics of ideal testosterone formulations Review

More information

Androgenes and Antiandrogenes

Androgenes and Antiandrogenes Androgenes and Antiandrogenes Androgens The androgens are a group of steroids that have anabolic and/or masculinizing effects in both males and females. Testosterone [tess-toss-terone], the most important

More information

TREATMENT OPTIONS FOR MALE HYPOGONADISM

TREATMENT OPTIONS FOR MALE HYPOGONADISM TREATMENT OPTIONS FOR MALE HYPOGONADISM Bruce Biundo, RPh, FACA PCCA Pharmacy Consulting Department Updated July 2012 Hypogonadism in men is primarily a state involving lower than expected levels of testosterone,

More information

PRODUCT INFORMATION TESTOVIRON DEPOT. (testosterone enanthate)

PRODUCT INFORMATION TESTOVIRON DEPOT. (testosterone enanthate) PRODUCT INFORMATION TESTOVIRON DEPOT (testosterone enanthate) NAME OF THE MEDICINE Testosterone enanthate is designated chemically as 17 beta-heptanoyloxy-4-androstene-3- one. The empirical formula of

More information

The Testosterone Quandary. Beth Crowder, PhD, APRN

The Testosterone Quandary. Beth Crowder, PhD, APRN The Testosterone Quandary Beth Crowder, PhD, APRN Objectives Define testosterone, the hypothalamic-pituitary-gonadotrophic axis, and normal blood levels List functions of testosterone and symptoms of low

More information

Elements for a public summary

Elements for a public summary VI.2 VI.2.1 Elements for a public summary Overview of disease epidemiology Prostate gland enlargement is a common condition as men get older. Also called benign prostatic hyperplasia (BPH) and prostatic

More information

SUMMACARE COMMERCIAL MEDICATION REQUEST GUIDELINES TESTOSTERON. Generic Brand HICL GCN Exception/Other ROUTE MISCELL.

SUMMACARE COMMERCIAL MEDICATION REQUEST GUIDELINES TESTOSTERON. Generic Brand HICL GCN Exception/Other ROUTE MISCELL. Generic Brand HICL GCN Exception/Other ANDRODERM 01403 ROUTE MISCELL. ANDROGEL AXIRON FORTESTA NATESTO STRIANT TESTIM VOGELXO DEPO- 01400 ROUTE MISCELL. CYPIONATE TESTOSTERON E GCN 38586 DELATESTRYL 01401

More information

1001 West Broadway, Vancouver, BC V6H 4B1. Topical Finasteride

1001 West Broadway, Vancouver, BC V6H 4B1. Topical Finasteride 1001 West Broadway, Vancouver, BC V6H 4B1 Topical Finasteride 1 Topical finasteride is a solution containing the drug finasteride typically sold under the brand names Propecia and Proscar. The Finasteride

More information

FINASTERIDE (PROPECIA, PROSCAR) SIDE EFFECT & CONSENT FORM

FINASTERIDE (PROPECIA, PROSCAR) SIDE EFFECT & CONSENT FORM 750 West Broadway Street Suite 905 Vancouver, BC M5Z 1K1 FAX: (604) 648-9003 vancouveroffice@donovanmedical.com FINASTERIDE (PROPECIA, PROSCAR) SIDE EFFECT & CONSENT FORM What is finasteride? Finasteride

More information

Medical Policy Testosterone Therapy

Medical Policy Testosterone Therapy Medical Policy Testosterone Therapy Subject: Testosterone Therapy Effective Date: April 2015 Overview: Testosterone cypionate, testosterone enanthate, testosterone undecanoate, and testosterone pellet

More information

Adverse effects of anabolic androgenic steroids abuse on gonadal function, glucose homeostasis and cardiovascular function

Adverse effects of anabolic androgenic steroids abuse on gonadal function, glucose homeostasis and cardiovascular function Adverse effects of anabolic androgenic steroids abuse on gonadal function, glucose homeostasis and cardiovascular function Associate Professor Caroline Kistorp, Ph.D Department of Internal Medicine, Herlev

More information

Clinical Policy: Testosterone Reference Number: AZ.CP.PHAR.02 Effective Date: Last Review Date: Line of Business: Arizona Medicaid

Clinical Policy: Testosterone Reference Number: AZ.CP.PHAR.02 Effective Date: Last Review Date: Line of Business: Arizona Medicaid Clinical Policy: Reference Number: AZ.CP.PHAR.02 Effective Date: 11.16.16 Last Review Date: 09.12.18 Line of Business: Arizona Medicaid Revision Log See Important Reminder at the end of this policy for

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: Reference Number: CP.CPA.291 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important regulatory

More information

A mathematical comparison of techniques to predict biologically available testosterone in a cohort of 1072 men

A mathematical comparison of techniques to predict biologically available testosterone in a cohort of 1072 men European Journal of Endocrinology (2004) 151 241 249 ISSN 0804-4643 EXPERIMENTAL STUDY A mathematical comparison of techniques to predict biologically available testosterone in a cohort of 1072 men Paul

More information

Elements for a Public Summary. Overview of disease epidemiology

Elements for a Public Summary. Overview of disease epidemiology VI.2 VI.2.1 Elements for a Public Summary Overview of disease epidemiology Benign prostatic hyperplasia (BPH) (an increase in size of the prostate that is not cancerous) is the most prevalent of all diseases

More information

The Science of. NUTRICULA Longevity Journal

The Science of. NUTRICULA Longevity Journal 32 December, 2011 The Science of 33 NUTRICULA Longevity Journal As men age, there is often a decline in libido and sexual function. This decline frequently interferes in intimacy within romantic relationships,

More information

September 17, FDA background documents for the discussion of two major issues in testosterone replacement therapy (TRT):

September 17, FDA background documents for the discussion of two major issues in testosterone replacement therapy (TRT): JOINT MEETING FOR BONE, REPRODUCTIVE AND UROLOGIC DRUGS ADVISORY COMMITTEE (BRUDAC) AND THE DRUG SAFETY AND RISK MANAGEMENT ADVISORY COMMITTEE (DSARM AC) September 17, 2014 FDA background documents for

More information

OF THE one thousand generations of humans that have

OF THE one thousand generations of humans that have 0021-972X/98/$03.00/0 Vol. 83, No. 10 Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright 1998 by The Endocrine Society THERAPEUTIC PERSPECTIVE Issues in Testosterone Replacement

More information

PRODUCT INFORMATION PROVIRON

PRODUCT INFORMATION PROVIRON PRODUCT INFORMATION PROVIRON NAME OF TE MEDICINE Mesterolone is a white to yellowish crystalline powder and is practically insoluble in water. The chemical name for mesterolone is 17 beta-ydroxy-1 alpha-methyl-5

More information

Inappropriate Testosterone Billings

Inappropriate Testosterone Billings Inappropriate Testosterone Billings Carla Patrick-Fagan March 30, 2015 Truven Health Analytics Inc. All Rights Reserved. 1 Agenda Proposed in the 2015 analytic plan Steroid prescriptions Code of Federal

More information

Associate Professor Geoff Braatvedt

Associate Professor Geoff Braatvedt Associate Professor Geoff Braatvedt Endocrinologist Diabetologist and Physician Green Lane and Auckland City Hospitals Auckland 14:00-14:55 WS #145: Approach to Low Testosterone Values 15:05-16:00 WS #157:

More information

All About T Testosterone for FTMs. Presented by John Otto, MLIS

All About T Testosterone for FTMs. Presented by John Otto, MLIS All About T Testosterone for FTMs Presented by John Otto, MLIS Who? Anyone thinking about transitioning Those who have transitioned, but want to know more Empowerment from self-managing transition Allies

More information

Package Leaflet: Information for the patient. Sustanon 250, 250 mg/ml, solution for injection (testosterone esters)

Package Leaflet: Information for the patient. Sustanon 250, 250 mg/ml, solution for injection (testosterone esters) Package Leaflet: Information for the patient Sustanon 250, 250 mg/ml, solution for injection (testosterone esters) Read all of this leaflet carefully before you start using this medicine because it contains

More information

Reproductive DHT Analyte Information

Reproductive DHT Analyte Information Reproductive DHT Analyte Information - 1 - DHT Introduction Dihydrotestosterone (DHT) together with other important steroid hormones such as testosterone, androstenedione (ASD) and dehydroepiandrosterone

More information

FINCAR Tablets (Finasteride)

FINCAR Tablets (Finasteride) Published on: 10 Jul 2014 FINCAR Tablets (Finasteride) Composition FINCAR Tablets Each film-coated tablet contains: Finasteride USP - 5 mg Dosage Form Tablet Pharmacology Pharmacodynamics Mechanism of

More information

TESTOFEN HUMAN CLINICAL TRIAL GENCOR PACIFIC, INC. Copyright 2006 by Gencor Pacific, Inc.

TESTOFEN HUMAN CLINICAL TRIAL GENCOR PACIFIC, INC. Copyright 2006 by Gencor Pacific, Inc. GENCOR PACIFIC, INC. 920 E. Orangethorpe Avenue, Suite B, Anaheim, CA 92801 Ph: 714.870.8723 714.870.8724 efax: 732.875.0306 drjit@gencorpacific.com gita@gencorpacific.com www.gencorpacific.com TESTOFEN

More information

Month/Year of Review: September 2013 Date of Last Review: December 2009

Month/Year of Review: September 2013 Date of Last Review: December 2009 Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119 Copyright 2013 Oregon State University. All Rights

More information

Female testosterone level chart

Female testosterone level chart Female testosterone level chart The Borg System is 100 % Female testosterone level chart Mar 23, 2015. Male, Female. Age: T Level (ng/dl):, Age: T Level (ng/dl):. 0-5 mo. 75-400, 0-5 mo. 20-80. 6 mos.-9

More information

Robert Perlstein, M.D. Medical Officer. Center for Drug Evaluation and Research. U.S. Food & Drug Administration

Robert Perlstein, M.D. Medical Officer. Center for Drug Evaluation and Research. U.S. Food & Drug Administration -------------------- Robert Perlstein, M.D. Medical Officer Center for Drug Evaluation and Research U.S. Food & Drug Administration -------------------- Sentencing of Food and Drug Offenses Before the

More information

MALE HORMONE THERAPY OPTIONS

MALE HORMONE THERAPY OPTIONS MALE HORMONE THERAPY OPTIONS The following tables have been compiled by Women s staff pharmacists to represent some of the more frequently prescribed regimens for men. The Women s logo is placed throughout

More information

PRODUCT INFORMATION PRIMOTESTON DEPOT. (testosterone enantate)

PRODUCT INFORMATION PRIMOTESTON DEPOT. (testosterone enantate) PRODUCT INFORMATION PRIMOTESTON DEPOT (testosterone enantate) NAME OF THE MEDICINE Testosterone enantate is designated chemically as 17 beta-heptanoyloxy-4-androstene-3- one. The empirical formula of testosterone

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association Androgens and Anabolic Steroids Page 1 of 57 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Androgens and Anabolic Steroids Prime Therapeutics will review Prior

More information

Icd-10 low levels of testosterone

Icd-10 low levels of testosterone Icd-10 low levels of testosterone The Borg System is 100 % Icd-10 low levels of testosterone 1-10-2017 if your hormone levels are too high or too low, you may have a hormone disorder. Hormone diseases

More information

Dr Tarza Jamal Pharmacology Lecture 2

Dr Tarza Jamal Pharmacology Lecture 2 Contraceptives and androgen hormone Contraceptives: Currently, interference with ovulation is the most common pharmacologic intervention for preventing pregnancy. Major classes of contraceptives 1. Combination

More information

Pros and Cons of Hormone Testing in Different Body Fluids with Different Routes of Hormone Delivery

Pros and Cons of Hormone Testing in Different Body Fluids with Different Routes of Hormone Delivery Pros and Cons of Hormone Testing in Different Body Fluids with Different Routes of Hormone Delivery David T Zava, PhD ZRT laboratory A Guide to Steroid Hormone Testing in Different Body Fluids Following

More information

Medication Policy Manual

Medication Policy Manual Independent licensees of the Blue Cross and Blue Shield Association Medication Policy Manual Topic: Non-preferred, non-transdermal testosterone replacement therapy products (Android, Aveed, Androxy, Methitest,

More information

Male Hormone Replacement Therapy. Punita Dhindsa D.O PGY 2

Male Hormone Replacement Therapy. Punita Dhindsa D.O PGY 2 Male Hormone Replacement Therapy Punita Dhindsa D.O PGY 2 Physiology of Testosterone & Causes of Hypogonadism in Males The use of testosterone therapy is very common in the US, with an estimated 2.3 million

More information

SUMMARY and OBJECTIVES. LOW T- I m half the man I used to be. Prevalence of Low-T. Definition of Hypogonadism 9/19/ Million men in the US

SUMMARY and OBJECTIVES. LOW T- I m half the man I used to be. Prevalence of Low-T. Definition of Hypogonadism 9/19/ Million men in the US SUMMARY and OBJECTIVES LOW T- I m half the man I used to be A discussion of male hypogonadism David Doriguzzi, PA-C Valley Endocrine & Diabetes Consultants Definition Prevalence Causes Signs & Symptoms

More information

XYOSTED (testosterone enanthate) injection, for subcutaneous use CIII Initial US approval: 1953 IMPORTANT SAFETY INFORMATION

XYOSTED (testosterone enanthate) injection, for subcutaneous use CIII Initial US approval: 1953 IMPORTANT SAFETY INFORMATION ANTARES PHARMA ANNOUNCES THE COMMERCIAL AVAILABILITY OF XYOSTED (TESTOSTERONE ENANTHATE) INJECTION A NEW TREATMENT FOR ADULT MEN DIAGNOSED WITH TESTOSTERONE DEFICIENCY XYOSTED - A Novel Subcutaneous Testosterone

More information

Long-term experience with testosterone replacement through scrotal skin

Long-term experience with testosterone replacement through scrotal skin CHAPTER 13 1 Long-term experience with testosterone replacement through scrotal skin Linda E. Atkinson, Yu-Lin Chang, and Peter J. Snyder Contents 13.1 13.1.1 13.1.2 13.2 13.2.1 13.2.2 13.2.2.1 13.2.2.2

More information

DUPROST Capsules (Dutasteride)

DUPROST Capsules (Dutasteride) Published on: 10 Jul 2014 DUPROST Capsules (Dutasteride) Composition Each soft gelatin capsule contains: Dutasteride... 0.5 mg Dosage Form Capsule Pharmacology Pharmacodynamics Mechanism of Action Dutasteride

More information

PRODUCT INFORMATION. Testosterone Phenylpropionate: Testosterone Phenylpropionate is 3-oxoandrost-4-en-17β-yl

PRODUCT INFORMATION. Testosterone Phenylpropionate: Testosterone Phenylpropionate is 3-oxoandrost-4-en-17β-yl PRODUCT INFORMATION SUSTANON '250' NAME OF THE MEDICINE Sustanon '250' ('250' mg/ml for injection): testosterone propionate, testosterone phenylpropionate, testosterone isocaproate, testosterone decanoate.

More information

New long-acting androgens

New long-acting androgens World J Urol (2003) 21: 306 310 DOI 10.1007/s00345-003-0364-x TOPIC PAPER Louis J. Gooren New long-acting androgens Received: 16 September 2003 / Accepted: 17 September 2003 / Published online: 9 October

More information

Risks and benefits of testosterone therapy in older men. Matthew Spitzer, Grace Huang, Shehzad Basaria, Thomas G. Travison and Shalender Bhasin

Risks and benefits of testosterone therapy in older men. Matthew Spitzer, Grace Huang, Shehzad Basaria, Thomas G. Travison and Shalender Bhasin Risks and benefits of testosterone therapy in older men Matthew Spitzer, Grace Huang, Shehzad Basaria, Thomas G. Travison and Shalender Bhasin Abstract In young men (defined as age

More information

The physiology of normal androgen production in

The physiology of normal androgen production in Mayo Clin Proc, April 2004, Vol 79 (Supplement) Formulations and Use of Androgens S3 Supplement Article Formulations and Use of Androgens in Women MICHELINE C. CHU, MD, AND ROGERIO A. LOBO, MD The physiology

More information

Cigna Drug and Biologic Coverage Policy

Cigna Drug and Biologic Coverage Policy Cigna Drug and Biologic Coverage Policy Subject Implantable Hormone Pellets Table of Contents Coverage Policy... 1 General Background... 3 Coding/Billing Information... 5 References... 6 Effective Date...

More information

PHYSICIANS CIRCULAR FINASTERIDE PROSCAR. Tablet 5-Alpha Reductase Inhibitor

PHYSICIANS CIRCULAR FINASTERIDE PROSCAR. Tablet 5-Alpha Reductase Inhibitor PHYSICIANS CIRCULAR FINASTERIDE PROSCAR Tablet 5-Alpha Reductase Inhibitor FINASTERIDE (PROSCAR) a synthetic 4-azasteroid compound, is a specific inhibitor of Type II 5α-reductase, an intracellular enzyme

More information

Testosterone Effects in Transmen

Testosterone Effects in Transmen Transmen Testosterone Effects in Transmen EFFECT Skin oiliness/acne Facial/body hair growth Scalp hair loss Increased muscle mass/strength Fat redistribution Cessation of menses Clitoral enlargement Vaginal

More information

Testosterone as a Therapeutic Tool

Testosterone as a Therapeutic Tool 330 Medicine Update 56 Testosterone as a Therapeutic Tool SV MADHU INTRODUCTION Testosterone preparations have been available for many years and have been used by physicians primarily to treat sexual problems.

More information

AS our population ages, concerns about frailty and

AS our population ages, concerns about frailty and Journal of Gerontology: MEDICAL SCIENCES 2004, Vol. 59A, No. 5, 461 465 Copyright 2004 by The Gerontological Society of America Special Article Masculine Vitality: Pros and Cons of Testosterone in Treating

More information

Male hypogonadism is a clinical syndrome that

Male hypogonadism is a clinical syndrome that Journal of Andrology, Vol. 33, No. 4, July/August 2012 Copyright E American Society of Andrology A Novel Testosterone 2% Gel for the Treatment of Hypogonadal Males ADRIAN S. DOBS,* JOHN MCGETTIGAN,{ PAUL

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association Androgens and Anabolic Steroids Page 1 of 53 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Androgens and Anabolic Steroids Prime Therapeutics will review Prior

More information

Gynaecomastia. Benign breast conditions information provided by Breast Cancer Care

Gynaecomastia. Benign breast conditions information provided by Breast Cancer Care Gynaecomastia This booklet tells you about gynaecomastia. It explains what gynaecomastia is, what causes it, how it s diagnosed and what will happen if it needs to be treated or followed up. Benign breast

More information

Monitoring Hormone Therapy Mark Newman, M.S. President of Precision Analytical Inc.

Monitoring Hormone Therapy Mark Newman, M.S. President of Precision Analytical Inc. Mr Mark Newman Monitoring Hormone Therapy Mark Newman, M.S. President of Precision Analytical Inc. 2 Avoiding Pitfalls in (B)HRT Monitoring and Picking the Right Lab Test Objectives: Outline how expected

More information

Mens Health Post Puberty. Nayan Patel PharmD

Mens Health Post Puberty. Nayan Patel PharmD Mens Health Post Puberty Nayan Patel PharmD Definition of Androgen Deficiency * Consistently low testosterone * Associated signs/symptoms * Evidence based review of literature * Data is weak at best Definition

More information

Cinryze. Cinryze (C1 esterase inhibitor [human]) Description

Cinryze. Cinryze (C1 esterase inhibitor [human]) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.85.05 Subject: Cinryze Page: 1 of 5 Last Review Date: September 20, 2018 Cinryze Description Cinryze

More information

Andropause How Relevant?

Andropause How Relevant? Andropause How Relevant? 323 55 Andropause How Relevant? VN MISHRA, NALINI MISHRA INTRODUCTION In day-to-day practice it is not unusual to encounter male patients in their 50s or older who come to physician

More information

AndroGel. (testosterone gel) 1% H 3 C

AndroGel. (testosterone gel) 1% H 3 C 1 AndroGel (testosterone gel) 1% 500122/500127 Rev Dec 2004 DESCRIPTION AndroGel (testosterone gel) is a clear, colorless hydroalcoholic gel containing 1% testosterone. AndroGel provides continuous transdermal

More information

Hypogonadism and Testosterone Replacement Therapy

Hypogonadism and Testosterone Replacement Therapy Testosterone Replacement Therapy Hypogonadism and Testosterone Replacement Therapy a report by Adrian S Dobs, MD, MHS and Anjana Myneni, MD Professor of Medicine and Oncology, Department of Medicine, Johns

More information

TESTIM (testosterone gel) for topical use, CIII Initial U.S. Approval: 1953

TESTIM (testosterone gel) for topical use, CIII Initial U.S. Approval: 1953 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use TESTIM safely and effectively. See full prescribing information for TESTIM. TESTIM (testosterone

More information

4.2 Posology, method and duration of administration

4.2 Posology, method and duration of administration The format of this leaflet was determined by the Ministry of Health and its content was checked and approved by it in May 2011. 1. NAME OF MEDICINAL PRODUCT Testoviron Depot Oily solution for injection

More information

Updates on Anti-doping and TUE Management in Paralympic Sport

Updates on Anti-doping and TUE Management in Paralympic Sport International Paralympic Committee Updates on Anti-doping and TUE Management in Paralympic Sport Matthew Fedoruk, Ph.D. March 15, 2018 PyeongChang 2018 IPC Medical / Sports Science Committee Workshops

More information

Relationship between Aerobic Training and Testosterone Levels in Male Athletes

Relationship between Aerobic Training and Testosterone Levels in Male Athletes Relationship between Aerobic Training and Testosterone Levels in Male Athletes Siu Yuen Ng Biology 493 13 th December, 2010 Abstract Salivary testosterone levels of 11 athletes and 15 non athletes were

More information

Author of: The Six-Pack Diet Plan: The Secrets to Getting Lean Abs and a Rock-Hard Body Permanently

Author of: The Six-Pack Diet Plan: The Secrets to Getting Lean Abs and a Rock-Hard Body Permanently Interview with Rehan Jalali, President, Supplement Research Foundation Author of: The Six-Pack Diet Plan: The Secrets to Getting Lean Abs and a Rock-Hard Body Permanently Background Information: According

More information

Gonadal Steroids and Body Composition, Strength, and Sexual Function in Men

Gonadal Steroids and Body Composition, Strength, and Sexual Function in Men T h e n e w e ngl a nd j o u r na l o f m e dic i n e original article Gonadal Steroids and Body Composition, Strength, and Sexual Function in Men Joel S. Finkelstein, M.D., Hang Lee, Ph.D., Sherri-Ann

More information

See 17 for PATIENT COUNSELING INFORMATION and Medication o 50 mg/0.5 ml. Revised: 09/2018 o 100 mg/0.5 ml

See 17 for PATIENT COUNSELING INFORMATION and Medication o 50 mg/0.5 ml. Revised: 09/2018 o 100 mg/0.5 ml HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use XYOSTED safely and effectively. See full prescribing information for XYOSTED. XYOSTED (testosterone

More information

Although women produce only

Although women produce only For mass reproduction, content licensing and permissions contact Dowden Health Media. Mary Lake Polan, MD, PhD, MPH Katharine Dexter McCormick and Stanley McCormick Memorial Professor and Chair Emeritus,

More information

If looking for a book Testosterone: Boost Testosterone Naturally - For - Weight Loss, Muscle Building, Libido & Erectile Dysfunction (Testosterone

If looking for a book Testosterone: Boost Testosterone Naturally - For - Weight Loss, Muscle Building, Libido & Erectile Dysfunction (Testosterone Testosterone: Boost Testosterone Naturally - For - Weight Loss, Muscle Building, Libido & Erectile Dysfunction (Testosterone Enanthate, Testosterone Replacement... Pressure, Tongkat Ali, Increase Testo)

More information

PRESCRIBING INFORMATION

PRESCRIBING INFORMATION PRESCRIBING INFORMATION C DELATESTRYL* testosterone enanthate Solution for Injection, 200 mg/ml Androgens Valeant Canada LP 2150 Blvd. St-Elzear West Laval, Quebec H7L 4A8 Date of Revision: August 19,

More information

MALE HORMONE THERAPY OPTIONS

MALE HORMONE THERAPY OPTIONS MALE HORMONE THERAPY OPTIONS The following tables have been compiled by Women s International Pharmacy staff pharmacists to represent some of the more frequently prescribed regimens for men. The Women

More information

Persistent depression? Low libido?

Persistent depression? Low libido? Persistent depression? Low libido? 24 Androgen decline may be to blame Cyril decommarque / Photonica Low serum testosterone can often be corrected without using hormones, such as by changing or supplementing

More information

ANDROGENS PLAY AN essential role in the sexual

ANDROGENS PLAY AN essential role in the sexual 0021-972X/04/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 89(11):5429 5434 Printed in U.S.A. Copyright 2004 by The Endocrine Society doi: 10.1210/jc.2004-0897 Intramuscular Testosterone

More information

presents with Dr. Paul Savage, MD

presents with Dr. Paul Savage, MD presents Pioneering Nutz & Boltz Technologies of BHT: For Lifestyle Male Case Based Studies Medicine with Dr. Paul Savage, MD o Founder of Power2Practice Integrative Medicine EMR o Founder and Director

More information

Running head: Extremely low testosterone due to RED-S

Running head: Extremely low testosterone due to RED-S AACE Clinical Case Reports Rapid Electronic Articles in Press Rapid Electronic Articles in Press are preprinted manuscripts that have been reviewed and accepted for publication, but have yet to be edited,

More information

Are Steroids Worth the Risk?

Are Steroids Worth the Risk? Are Steroids Worth the Risk? Dominic has baseball on the brain. Just being good isn't enough he wants to be the best. He dreams of playing in the majors someday, but worries about the intense competition

More information

Testim 1% PRODUCT MONOGRAPH. (testosterone gel) Androgens. Paladin Labs Inc. 100 Alexis Nihon Blvd., Suite 600 St. Laurent, Quebec H4M 2P2

Testim 1% PRODUCT MONOGRAPH. (testosterone gel) Androgens. Paladin Labs Inc. 100 Alexis Nihon Blvd., Suite 600 St. Laurent, Quebec H4M 2P2 PRODUCT MONOGRAPH C Testim 1% (testosterone gel) Androgens Paladin Labs Inc. 100 Alexis Nihon Blvd., Suite 600 St. Laurent, Quebec H4M 2P2 Date of Revision: February 3, 2017 Control No: 201331-1 - Table

More information

Initial trial of slow-release testosterone microspheres in hypogonadal men*

Initial trial of slow-release testosterone microspheres in hypogonadal men* FERTILITY AND STERILITY Copyright c 1988 The American Fertility Society Printed in U.S.A. Initial trial of slow-release testosterone microspheres in hypogonadal men* Allen S. Burris, M.D. t Larry L. Ewing,

More information

Policy. covered: bilateral. alcohol or. Approve. 3. Palliative enanthate injection in. women for. 6 months if. can also sponsive tumor.

Policy. covered: bilateral. alcohol or. Approve. 3. Palliative enanthate injection in. women for. 6 months if. can also sponsive tumor. Injectablee Testosterone Products Prior Authorization Policy Number: 5.01.597 Origination: 07/2014 Last Review: 07/2014 Next Review: 07/2015 Policy BCBSKC will provide coverage for injectable testosterone

More information

Transgender 201: Case Discussion Group

Transgender 201: Case Discussion Group Transgender 201: Case Discussion Group Melissa Davis, MD Maria Barnett, DO October 19, 2017 Maria Barnett, DO, Date Welcome! Disclosures Introductions Discussion The total time of this workshop will depend

More information

Use of Performance Enhancing Substances Good Chemistry Gone Bad. Evan M. Klass, M.D., F.A.C.P.

Use of Performance Enhancing Substances Good Chemistry Gone Bad. Evan M. Klass, M.D., F.A.C.P. Use of Performance Enhancing Substances 2017 Good Chemistry Gone Bad Evan M. Klass, M.D., F.A.C.P. Doping the use of banned athletic performance-enhancing drugs by competitors Performance enhancing substances

More information